VENUS®
Enjoy Innovations

VRL/SEC/NSE 03.08.2013

National Stock Exchange of India Ltd.
5th Floor , Exchange Plaza
Bandra (E),
Mumbai- 400 051

Sub.: Unaudited Financial Results (Provisional) for the quarter ended on 30.06.2013

Dear Sir/Madam,

Please find enclosed herewith copy of Unaudited Financial Results (Provisional) for the quarter ended on 30.06.2013 along with the limited review which were taken on record by the Board of Directors at its meeting held on 03.08.2013

Kindly acknowledge the receipt.

Thanking you.

Yours faithfully,
for VENUS REMEDIES LIMITED

Neha Kodan
(Company Secretary)

AN ISO 9001:2008 : ISO 14001-2004 : OHSAS 18001 - 2007
EU - GMP
CERTIFIED COMPANY

VENUS REMEDIES LIMITED
Corporate Office :
51-52, Industrial Area, Phase- I,
Panchkula (Hry.) 134113, India
Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC,
Manimajra, Chandigarh (U.T.) 160101, India
Website : www.venusremedies.com
www.venusmedicineresearchcentre.com

MOODY INTERNATIONAL
UKAS QUALITY MANAGEMENT
UKAS ENVIRONMENTAL MANAGEMENT

Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566
Unit-II :
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272
Unit-V :
VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368, Werne, Germany

VENUS®
Enjoy Innovations

UNAUDITED FINANCIAL RESULTS (PROVISIONAL)
FOR THE QUARTER ENDED 30TH JUNE, 2013

Rs. IN MILLION

S. No.	PARTICULARS	Quarter Ended on			Year Ended on
		30/06/2013	31/03/2013	30/06/2012	31/03/2013
	Part – I	Unaudited	Unaudited	Unaudited	Audited
1	**Net Sales/ Income from operations**				
	Gross Sales	1268.79	1253.11	1123.75	4,602.58
	Less : Excise Duty	2.34	2.83	3.41	11.61
	(a) Net Sales	1266.45	1250.28	1120.34	4,590.97
	(b) Other Operating Income	5.63	2.89	5.38	22.41
	Total Income from Operation (Net)	**1,272.08**	**1,253.17**	**1,125.72**	**4,613.38**
2	**Expenses**				
	(a) Consumption of raw materials	752.50	785.68	652.37	2,725.58
	(b) (Increase)/ Decrease in stock in trade	-2.80	-31.83	-29.75	-92.93
	(c) Employee benefits expense	59.17	58.87	57.10	232.38
	(d) Depreciation & amortization expense	95.35	80.07	77.69	317.62
	(e) Other expenses	147.14	139.68	148.80	563.47
	Total expense	**1,051.36**	**1,032.47**	**906.21**	**3,746.12**
3	**Profit from operations before other income , finance costs and exceptional items (1-2)**	**220.72**	**220.70**	**219.51**	**867.26**
4	Other income	8.18	-3.45	1.26	3.95
5	**Profit before finance costs and exceptional items (3+4)**	**228.90**	**217.25**	**220.77**	**871.21**
6	Finance Costs	66.81	61.68	76.15	244.49
7	**Profit after finance costs but before exceptional items (5-6**	**162.09**	**155.57**	**144.62**	**626.72**
8	Exceptional items	0.00	0	0.00	00.00
9	**Profit from ordinary activities before tax (7+8)**	**162.09**	**155.57**	**144.62**	**626.72**
10	Tax expense	8.97	36.04	4.17	55.27
11	**Profit from ordinary activities after tax (9-10)**	**153.12**	**119.53**	**140.45**	**571.45**
12	Exceptional items (net of tax expense	00.00	0.00	00.00	0.00
13	**Net profit for the period (11-12)**	**153.12**	**119.53**	**140.45**	**571.45**
14	**Paid up Equity Share Capital**	**114.42**	**105.42**	**97.42**	**105.42**
15	**Reserves excluding revaluation reserves**	**N. A.**	**N. A.**	**N. A.**	**3,769.22**
16	**E.P.S - Basic not annualised for the qtr**	**13.38**	**11.34**	**14.42**	**54.21**
	- Annualised	**53.53**	**45.35**	**57.67**	**54.21**
	Part – II (A)				
1	**Public Shareholding**				
	- Number of Shares	6437086	6437086	6388986	6437086
	- Percentage of Shareholding	56.26	61.06	65.58	61.06
2	**Promoters and promoter group shareholding**				
	a) Pledged as collateral security to bank				
	- Number of Shares	1930000	1930000	1930000	1930000
	- Percentage of shares (as a % of the total share holding of promoter and promoter group	38.56	47.02	57.56	47.02
	- Percentage of shares (as a % of the total share capital	16.87	18.31	19.81	18.31
	b) Non-Encumbered				
	- Number of Shares	3074902	2174902	1423002	2174902
	- Percentage of shares (as a % of the total share holding of promoter and promoter group	61.44	52.98	42.44	52.98
	- Percentage of shares (as a % of the total share capital	26.87	20.63	14.61	20.63

Particulars	3 months ended 30.06.13
(B) INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	NIL
Received during the quarter	1
Disposed of during the quarter	1
Remaining unresolved at the end of the quarter	NIL

For VENUS REMEDIES LIMITED

VENUS®
Enjoy Innovations

Notes:

1. The above Un-audited (Provisional) financial Results for the period ended 30.06.2013 were reviewed by the Audit Committee and taken on record at the board Meeting on August 3, 2013.

2. During the Quarter:

a) The Company has made it to the list of Top 100 in the "India's Best Companies to Work for" study conducted by the Great Place to Work Institute, India in association with The Economic Times Placed at the 72nd position.
b) The Company has received Mexico patent for its research product 'POTENTOX'.
c) The Company has been awarded Gold Medal by DST_Lockheed Martin India Innovation .growth program - 2013 for its research product 'ELORES'.
d) The Company out -licensed Elores a novel antibiotic adjuvant entity for South Korea after patent grant.

3. The Statutory Auditors have carried out Limited Review of the above Un- audited financial results in terms of Clause 41 of the listing Agreement.

4. During the Quarter, one investor grievance was received and resolved. No other investor grievance was pending at the end of the quarter.

5. The Company caters to only one segment i.e. "Pharmaceutical Formulations".

For and on behalf of Board of Directors
For VENUS REMEDIES LIMITED

Place : Panchkula
Date : 03.08.13

(Pawan Chaudhary)
Chairman & Managing Director

J. K. JAIN & ASSOCIATES

CHARTERED ACCOUNTANTS

S.C.O. 1132-33, Sector 22-B, CHANDIGARH - 160 022
0172-270 4536-37 Fax : 0172-270 4537
E-mail : jkjcaps@rediffmail.com

VENUS®
Enjoy Innovations

REVIEW REPORT

The Board of Directors,
Venus Remedies Limited
51-52, Industrial Area, Phase-I
Panchkula

We have reviewed the accompanying statement of un-audited Financial Results of **Venus Remedies Limited** for the Quarter ended 30.06.2013. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/Committee of Board Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, 'Engagements to Review financial statements' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of un-audited Quarterly financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of clause 41 of the listing agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

for J. K. Jain & Associates,
(Chartered Accountants)

J. K. JAIN & ASSOCIATES ☆ CHANDIGARH ☆ CHARTERED ACCOUNTANTS FRN 004025N

(Y.P. Gupta)
Partner
M.No. 089760

Date : 03.08.2013
Place : Chandigarh

CERTIFIED TO BE TRUE COPY

For Venus Remedies Limited

(Company Secretary)